Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Atcelts |
Versija | |
Datums | 2014-05-30 17:06:41 |
Versijas komentārs | |
Teksts |
Olaine, May 30, 2014
Olainfarm Sales in Q1 2014
Reach 23.3 Million Euro, Net Profit Grows by
32%
Q1 2014 has been the most profitable first quarter of the year in the
company's history ..... AS
“Olainfarm” ir aizvadījusi ienesīgāko pirmo ceturksni tās vēsturē,
sasniedzot 3,7 miljonu eiro peļņu un produktu realizāciju 23,3
miljonu eiro apmērā. Peļņa ir augusi par 32%, realizācija – par 4%,
salīdzinot ar šo periodu pērn. Major sales markets of JSC
Olainfarm during Q1 2014 were Russia, Ukraine, Latvia, Belarus and
the Netherlands.
„Neskatoties uz
saspīlējumiem Krievijas un Ukrainas attiecībās un nacionālās
valūtas tenge devalvāciju Kazahstānā, esam aizvadījuši ienesīgāko
pirmo ceturksni „Olainfarm” vēsturē. Šajā laikā ir izdevies
izlīdzsvarot pieprasītāko produktu realizācijas apjomus, sekmīgi
paplašināt reģistrētos produktus esošajos tirgos un nodrošināt
iespēju jau šogad sākt eksportu uz Mongoliju. Arvien vairāk pieaug
arī prettuberkulozes līdzekļa piegādes Pasaules Veselības
organizācijai,” norāda Valērijs Maligins, AS „Olainfarm”
valdes priekšsēdētājs.
During the 1st quarter of 2014 JSC
Olainfarm sales continued to increase in all of the company’s main
markets, except for Kazakhstan, where they decreased by 50%
year-on-year.
The decrease was due to devaluation of Kazakhstan national currency
tenge at the beginning of the year.
The biggest increases in sales
during Q1 2014 were achieved in Spain (+181%), Lithuania (+171%),
Ukraine (+157%) and Uzbekistan (+67%).
In total during three months of 2014 products of JSC Olainfarm were
sold to 31 countries in five continents.
During this period 12 registration cases have been approved in
several countries. Several products are still in the process of
obtaining MAs, among other countries, in Poland, Mongolia and
Kosovo. Preclinical trials of R-fenotropil are being conducted and
totally new forms of existing products are being
developed.
JSC Olainfarm budget and operating plan for 2014 sets targets for
consolidated sales to reach 93 million euro and net profit to reach
15 million euro. According to the unaudited report, during the 1st
quarter of 2014 25.1% of the annual sales target and 24.5% of the
annual profit target have been met.
JSC Olainfarm is one of the biggest pharmaceutical companies in
Latvia with more than 40 years of experience in production of
medication and chemical and pharmaceutical products. A basic
principle of company's operations is to produce reliable and
effective top quality products for Latvia and the rest of the
world. Products made by the Group are being exported to more than
35 countries of the world, including the Baltics, Russia, other
CIS, Europe, Asia, North America and Australia.
Information prepared
by: Salvis
Lapins JSC
“Olainfarm” Member of the Management
Board Rupnicu iela 5, Olaine, Latvia, LV
2114 Phone: +371 6 7013
717 Fax: +371 6 7013
777 e-mail: slapinsh@olainfarm.lv
|
Pielikumi |